BRAF and cutaneous melanoma: We report that, consistent with BRN2 playing a key role as a tumor suppressor in melanomagenesis, its locus is frequently lost in human skin cutaneous melanoma (SKCM) metastases, independently of their NRAS or BRAF status, and that BRN2 status contributes to overall patient survival.